Journal of Cytology
Home About us Ahead of print Instructions Submission Subscribe Advertise Contact e-Alerts Login 
Users Online:438
  Print this page  Email this page Small font sizeDefault font sizeIncrease font size


 
 Table of Contents    
ORIGINAL ARTICLE  
Year : 2020  |  Volume : 37  |  Issue : 4  |  Page : 193-199
Correlation between thyroid imaging reporting and data system and bethesda system of reporting of thyroid cytopathology of thyroid nodule: A single center experience


1 Department of Pathology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
2 Department of Radiology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
3 Department of Endocrinology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India

Click here for correspondence address and email

Date of Submission30-Apr-2019
Date of Decision21-Jun-2019
Date of Acceptance31-Jul-2020
Date of Web Publication16-Sep-2020
 

   Abstract 


Background: The incidence of thyroid cancer has been increasing worldwide. Thyroid imaging reporting and data system (TIRADS) has been proposed for risk stratification of thyroid nodules to improve categorical management. Fine needle aspiration cytology based on Bethesda system for reporting of thyroid cytopathology (BSRTC) plays a fundamental role in the evaluation of thyroid nodule microscopically. Both the systems, the TIRADS and the latest revised BSRTC 2017, are widely recommended and practiced all over the world, but the correlation between the two systems has not been established. Aims and Objectives: This study was conducted to assess the risk of malignancy (ROM) in the intermediate Bethesda categories of thyroid lesions and their correlation with the corresponding TIRADS categories. Materials and Method: It was a prospective cross-sectional study over 1 year including 69 patients aged 18 years or older having solitary thyroid nodules. All cases were triaged using both TIRADS and BSRTC 2017 and the diagnostic performances were compared with subsequent paraffin sections to evaluate ROM. Correlation between TIRADS and BSRTC systems was expressed as kappa value. Result: Good concordance was observed between TIRADS and BSRTC systems in the evaluation of benign thyroid nodule lesions (category 2-II). There was discordance in follicular lesions (category 4-IV). The kappa value generated (0.411) revealed moderate agreement between the two risk stratification systems. Conclusion: Careful application of both grading systems is essential for the proper segregation of thyroid nodules to facilitate effective clinical and surgical management. However, universally acceptable protocols need to be developed to avoid the heterogeneous approach.

Keywords: Bethesda, malignancy risk, thyroid nodule

How to cite this article:
Biswas A, Basu K, De S, Karmakar S, De D, Sengupta M, Ghosh S. Correlation between thyroid imaging reporting and data system and bethesda system of reporting of thyroid cytopathology of thyroid nodule: A single center experience. J Cytol 2020;37:193-9

How to cite this URL:
Biswas A, Basu K, De S, Karmakar S, De D, Sengupta M, Ghosh S. Correlation between thyroid imaging reporting and data system and bethesda system of reporting of thyroid cytopathology of thyroid nodule: A single center experience. J Cytol [serial online] 2020 [cited 2020 Nov 27];37:193-9. Available from: https://www.jcytol.org/text.asp?2020/37/4/193/295104





   Introduction Top


The prevalence of thyroid nodules by palpation is 3%–8% and by ultrasound (US) is 20%–76% in general population.[1] The incidence of thyroid cancer has been increasing worldwide in the last few decades.[2] This increase is almost exclusively attributed by papillary thyroid carcinoma than other histological subtypes of thyroid carcinoma.[3],[4] Introduction of highly sensitive detection method like high-resolution ultrasound is another contributor. Solitary thyroid nodule is a radiologically distinct discrete lesion with different echogenicity from surrounding thyroid parenchyma. Although US detects thyroid nodules more precisely, it differentiates benign from malignant lesion less accurately. Solid compositions, microcalcification, irregular margin, hypo-echogenicity, taller than wide shape, absent halo, and an increase in blood flow are the characteristic findings of malignancy in US. Based on the already existing breast imaging reporting and data system (BI-RADS) for breast nodule, an US-guided thyroid imaging reporting and data system (TIRADS) has been proposed for risk stratification of thyroid nodules to improve categorical management using this efficient low-cost measure.[5]

Fine needle aspiration (FNA) cytology plays a vital role in the initial diagnostic workup of solitary thyroid nodules. Evaluation and categorization can be improved by incorporating strategic system proposed by the latest revised Bethesda System for Reporting of Thyroid cytopathology (BSRTC-2017).[6] In spite of its intra and inter observer variability, pathologists worldwide are comfortable with this protocol. The Bethesda System classifies thyroid FNA findings into six categories with specific malignancy risks and guides in making further therapeutic decisions.

Both the systems—the TIRADS and BSRTC 2017—are widely recommended and practiced all over the world, but the correlation between the two systems has not been established. Our study is an effort to assess the correlation between the two systems.


   Materials and Methods Top


Study design

It was a prospective cross-sectional study conducted in the Department of Pathology in collaboration with the Department of Endocrinology and Department of Radiology in our tertiary care center over 1 year. A total of 69 patients aged 18 years or above having solitary thyroid nodule detected either clinically or radiologically and having subsequently undergone surgery were included. Patients with normal thyroid scan (TIRADS-1), history of previous thyroid surgery, and confirmed case of thyroid carcinoma (TIRADS-6) were excluded from the study. Ethical committee approval was taken on 14.1.2016 [Inst/IEC/2016/35].

Determination of sample size was done using www.openepi.com – Version 3.[7]

We calculated the sample size using the following formula:

Sample size n = [DEFF*Np (1-p)]/[(d2/Z21-α/2*(N-1)+p*(1-p)]

Population size (for finite population correction factor or fpc)(N): 1000000

Hypothesized % frequency of outcome factor in the population (p): 8%+/−5

Confidence limits as % of 100(absolute +/− %)(d): 5%

Design effect (for cluster surveys-DEFF): 1

Considering 90% confidence interval, 80 patients were initially incorporated in the study. But considering previously mentioned exclusion criteria, 11 patients were subsequently eliminated from study population.

Ethical committee approval was taken and informed consent was obtained from the participants of the study. A detailed analysis was performed to explore heterogeneity factors: age, sex, and nodule size.

After obtaining the signed consent, all the patients underwent US examination of the thyroid gland and FNA of the nodule was performed at the same sitting. The same radiologist read all the parameters (nodule size and shape, margins, internal content, echogenicity with presence or absence of echogenic foci) and categorized the lesion according to the TIRADS criteria by high-resolution ultrasound (PHILIPS HD7) using a 3–12 MHz broadband linear array transducer with selectable frequency and electronic focus. The FNA sample was stained with Papanicolaou and May–Grunwald–Giemsa (MGG) stain. Two experienced pathologists interpreted all the smears and categorized them according to Bethesda system (BSRTC-2017) [Table 1]. According to our institutional protocol, BSRTC-2017 recommendations were strictly followed for further management. As routine molecular pathology services are not available in our hospital, lobectomy was done in all cases of intermediate category for exact categorization. Tissue for final histopathology (HP) was obtained and formalin-fixed paraffin-embedded sections were examined by another pathologist for reporting according to WHO classification of tumors of endocrine organs (2017).[8]
Table 1: Thyroid imaging reporting and data system (TIRADS) and the Bethesda system for reporting cytopathology[5],[6]

Click here to view


Statistical analysis

The final histopathology report was considered as a gold standard and both TIRADS and Bethesda categories were compared accordingly. Risk of malignancy (ROM) was calculated as follows



The Kruskal–Wallis test was performed for comparisons between multiple TIRADS and BSRTC categories. The Chi-square (χ2) tests were analyzed for categorical evaluation. Correlations were evaluated using Spearman's rank correlation. P < 0.05 was considered as significant. Statistical software GRAPHPAD PRISM 5–Graph Pad Software, San Diego, CA 92108 was used for analysis.


   Result Top


A total of 69 patients were included in the study over a period of 1 year. Among all patients, female preponderance was seen, with male to female ratio 1:5.3 (P-value = 0.16). The mean age was 41.54 ± 11.86 years. A significant difference in age distribution was observed between Bethesda categories (P = 0.0322). It was lowest (41.82 ± 10.87) in Bethesda II and highest (48.6 ± 9.5) in Bethesda III and in between in Bethesda IV (43.23 ± 14.0) and V (44.30 ± 12.55). The mean diameter of the nodules was 3.25 ± 1.05 cm in BSRTC II, 2.38 ± 1.17 cm in BSRTC III, 3.48 ± 1.14 cm in BSRTC IV, and 5.69 ± 1.12 cm in BSRTC V. There was no striking difference in the size of the nodules in different Bethesda categories (P-value = 0.1012).

Of a total of 69 cases, there were 37 cases of category 2, 14 cases of category 3, 17 cases of category 4, and 1 case of category 5 according to TIRADS system. The rates of malignancies were 10.81%, 14.28%, 70.59%, and 100%, respectively. According to Bethesda system, there were 39 cases of category II, 10 cases of category III, 7 cases of category IV, and 13 cases of category V and the rates of malignancies were 5.13%, 20%, 28.57%, and 100% in categories II, III, IV, and V, respectively [Table 2] and [Figure 1].
Table 2: Malignancy risk according to the TIRAD and Bethesda system of reporting thyroid cytology (BSRTC)

Click here to view
Figure 1: Distribution of all cases according to TIRADS categories on ultrasonography

Click here to view


The highest correlation was found between TIRAD2 and Bethesda II. The frequency of category II of Bethesda was 39/69 (56.5%) vs. TIRAD 2 37/69 (53.62%). Among 32 concordant cases of TIRADS 2 and BSRTC II, colloid goiter was the most prevailing lesion. All cases of colloid goiter (n = 28) were accurately categorized by both radiology and cytology. Total four cases turned out to be papillary thyroid carcinoma and were categorized as BSRTC IV/V during cytological evaluation. Almost comparable results were found while measuring malignancy risk in TIRADS 2 (10.81) and BSRTC II (5.13%) [Figure 2].
Figure 2: BSRTC II: A case of Hashimoto thyroiditis showed an isoechoic lesion with a halo in radiology; low cellularity chiefly composed of dispersed small clusters of thyroid follicular cells on cytology (100 × and 400×, MGG stain) and lymphoid follicles with surrounding thyroid parenchyma on histopathology (100×, H and E stain)

Click here to view


Among the 14 cases of TIRADS 3, 6 nodules were in BSRTC III, 6 nodules in BSRTC II, and 1 case each in BSRTC IV and V, respectively. Both suspicious lesions were papillary thyroid carcinoma of classical and follicular variant on final histopathological evaluation. Cases of adenomatoid goiter were distributed in lower Bethesda category [Figure 3].
Figure 3: BSRTC III-A case of follicular adenoma showed equivocal echogenic foci with solid-cystic appearance on radiology; an intermediate size sheets with focal microfollicular appearance on cytology (100 × and 400×, MGG stain) and a well-encapsulated nodule with a microfollicular pattern on histopathology (100×, H and E stain)

Click here to view


There was a striking difference in the proportion of malignancy in TIRADS category 4 and BSRTC IV. TIRADS 4 included 17 cases of suspicious nodules and papillary thyroid carcinoma (9 cases) was the commonest lesions which were classified subsequently into BSRTC V according to cytomorphological features. Other two malignant lesions showed similar categorical distribution in BSRTC IV: one case was of follicular carcinoma and the other of Hurthle cell carcinoma. Both cases revealed repetitive follicular pattern on cytology. But, the case of lymphoma was cytologically underreported as BSRTC II. All these major disparities led to the conflicting ROM between TIRADS 4 (70.59%) and Bethesda IV (28.57%) [Figure 4].
Figure 4: BSRTC IV-A case of follicular variant of papillary thyroid carcinoma (FVPTC) showed a solid nodule in radiology; hypercellular smear with a repetitive microfollicular appearance on cytology (100 × and 400×, MGG stain) and follicular pattern with nuclear changes on histopathology (100×, H and E stain)

Click here to view


Although the number of cases was contrasting in TIRADS 5 (1 case; 1.45%) and BSRTC V (13 cases; 18.8%), both included only malignant cases which was the main concern during the evaluation of thyroid nodule. Case of anaplastic carcinoma that was reported as TIRADS 5 turned out subsequently as BSRTC V [Table 3] [[Figure 5].
Table 3: Distribution of cases in different TIRAD and BSRTC categories

Click here to view
Figure 5: BSRTC V-A case of papillary thyroid carcinoma showed hypoechoic taller than wider nodule in radiology, hypercellular smear with a large solid syncytial cluster on cytology (100 × and 400×, MGG stain) and papillae lined by neoplastic cells with nuclear clearing and overlapping on histopathology (100×, H and E stain)

Click here to view


Moderate agreement was observed between TIRADS and Bethesda systems (kappa value = 0.411). Among the benign lesions, adenomatoid nodules showed variable distribution in different TIRADS and Bethesda categories. On the other hand, papillary thyroid carcinoma was the malignant lesion which was reported as benign, intermediate, or suspicious lesion.


   Discussion Top


This study evaluated the correlation between TIRADS and Bethesda reporting systems for thyroid nodules. The female preponderance found in this study corroborated with previous literature.[2],[8],[9],[10] This was contributed mainly by Bethesda category II.[2] Females more commonly seek medical attention and there is an increased chance of detecting thyroid nodule either by palpation or by radiology. It is considered as “medical surveillance bias.” [11],[12]

After analyzing the results, our study showed a good correlation and concordance between TIRADS 2 and Bethesda II. In our study, 10.81% of cases categorized as TIRADS 2 showed malignancy, whereas 5.13% of cases considered as Bethesda II revealed malignant lesions on histopathology examination. On the contrary, the intermediate groups (TIRADS3 & 4) showed either higher or lower malignancy risk than their corresponding categories. Hence, in patients with extreme categories (TIRADS2 & 5), the diagnostic performance regarding the accurate segregation of benign and malignant lesions was more appreciable than the intermediate groups (TIRADS 3&4). The finding was consistent with previous studies.[13],[14],[15] Initially, the TIRADS system was developed to provide evidence-based recommendation using noninvasive imaging modality and to prevent overuse of minimally invasive FNA in this endocrine organ.[16] But during practical application, it was difficult to implement due to its complexity and inconsistent malignancy risk. Thus, it can be a supplement but cannot replace the role of FNA. [Table 4] showed a comparative analysis with prior published cases about diagnostic performance of TIRADS and BSRTC.
Table 4: A comparative analysis with prior published studies about diagnostic performance with combination of TIRADS and BSRTC

Click here to view


All Bethesda categories revealed slightly lower malignancy risks than corresponding TIRADS group except category 3-III. In Bethesda classification, category III with subgroups depending on morphology helps in better triaging of these lesions. Three categories in the BSRTC, namely, atypia of undetermined significance/follicular lesions of undetermined significance (AUS/FLUS), follicular neoplasm/suspicious of follicular neoplasm (FN/SFN), and suspicious of malignancy (SM) lesions show heterogeneity regarding clinical outcomes and pose difficulty to both pathologists and endocrinologists. Similarly, radiologists face dilemma during reporting the probably benign (category 3), suspicious (category 4), and probably malignant (category 5) nodules. Previously, we have analyzed the risk of neoplasm and risk of malignancies of six cytological subcategories of BSRTC III.[17] We documented that nuclear atypia with cyst macrophages was the cytological feature with highest ROM and Hurthle cell changes was the appearance with the lowest proportion of malignancy. One recent national article highlighted the differences in the management in different regions of the world and its impact on ROM.[18] Total 70.59% cases of TIRADS 4 showed a malignant lesion on final histology, whereas only 28.57% cases of Bethesda IV were found to be malignant. The original TIRADS classification also shows the ROM ranging from 5%–80% for TIRADS 4,[2] thus making this category less accurate to determine management strategies for the patient. But according to Bethesda classification 2017, malignancy risk for category IV is ranging from 15%–30% and in our study it was 28.57%. Suspicious nodules which are kept under TIRADS category 4 comprise mainly of follicular lesions of both benign (adenomatoid nodule) and malignant morphology (follicular variant of papillary thyroid carcinoma). Exact categorization of follicular lesion in FNA is difficult to interpret in majority of cases and needs surgical excision either in terms of lobectomy or near-total thyroidectomy. Similarly, during US reporting, follicular lesions appear as hypoechoic nodules. But the likelihood of malignancy gradually decreases from solid to solid-cystic to cystic lesion.[19] Among the benign lesions in intermediate categories, adenomatoid goiter was the most prevalent lesion. The radiological features of autoimmune diseases are enlargement in size of the gland along with hypervascularity and hypoechogenicity. All these US features can be encountered in diffusely infiltrative papillary or follicular thyroid carcinoma, therefore, leading to over diagnosis.[20]

The most reliable radiological features of benign lesion are the presence of circumferential uniform hallow and avascularity.[20] But a significant proportion of papillary thyroid carcinoma reveal similar features resulting in faulty categorization.[21] Srinivas et al. conducted a prospective study and concluded that five independent sonological features are significantly related to malignant cytology: Solid composition, marked hypoechogenicity, irregular margins, microcalcifications, and taller than wide shape. Among these features, irregular margins were the most sensitive for malignancy followed by taller than wide shape, microcalcification, marked hypoechogenicity, and solid composition in this order.[22] In our study, we found that variable combination of these features was helpful in the differentiation of benign from malignant nodules rather than any individual US appearance. According to another literature, microcalcification is the most reliable predictor of malignancy.[21] But, we found microcalcification in one case of follicular adenoma. Taki et al. reported a similar finding in the past.[23] In our study, papillary thyroid carcinoma revealed variable radiological features. It was postulated that US appearance changes according to histological subtype.[24] Follicular variant is reported as a benign lesion in most of the instances.

According to American Thyroid Association (ATA) guideline, TIRADS followed by FNA examination of thyroid nodule shows better reproducibility in terms of advocating more invasive procedures.[16] One previous study showed that depending on the presence of different US patterns along with FNA study categorizing an individual as low risk, intermediate risk, and high risk enables optimal clinical decision making regarding management strategies.[25]

Limitation of our study: Our prospective study was conducted including 69 cases only and, therefore, larger series with follow-up data would be useful for substantiation.

In conclusion, there is a good concordance between US report using TIRAD criteria and FNA using Bethesda to evaluate thyroid nodule in benign lesion (2-II). There is discordance in suspicious nodules (4-IV). For accurate diagnosis and institution of more preserving surgery, a combination of TIRADS and BETHESDA is needed simultaneously. Both systems are complementary to each other. However, more extensive studies and standardized management protocols need to be developed to prevent heterogeneous approach.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, et al. American Association of clinical endocrinologists, associazione medici endocrinologi, and European thyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2010;16:468-75.  Back to cited text no. 1
    
2.
Vargas-Uricoechea H, Meza-Cabrera M, Herrera–ChaprroJ. Concordance between the TIRADS ultrasound criteria and the BETHESDA cytology criteria on the nontoxic thyroid nodule. Thyroid Res 2017;10:1.  Back to cited text no. 2
    
3.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:359–86.  Back to cited text no. 3
    
4.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancerstatistics, 2012. CA Cancer J Clin 2015;65:87–108.  Back to cited text no. 4
    
5.
Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, et al. ACR thyroid imaging, reporting and data system (TI-RADS): White paper of the ACR TI-RADS committee. J Am Coll Radiol 2017;14:587–95.  Back to cited text no. 5
    
6.
Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 2017;27:1341-6.  Back to cited text no. 6
    
7.
Sullivan KM, Dean A, Soe MM. OpenEpi: A web-based epidemiologic and statistical calculator for public health. Public Health Rep 2009;124:471-4.  Back to cited text no. 7
    
8.
Lloyd RV, Osamura RY, Klöppel G, Rosai J, editors. WHO Classification of Tumours of Endocrine Organs. 4th ed.. Lyon, France: IARC; 2017.  Back to cited text no. 8
    
9.
Yoon JH, Lee HS, Kim EK, Moon HJ, Kwak JY. Thyroid nodules: Nondiagnostic cytologic results according to thyroid imaging reporting and data system before and after application of the bethesda system. Radiology 2015;276:579-87.  Back to cited text no. 9
    
10.
Al-Ghanimi IA, Al-Sharydah AM, Al-Mulhim S, Faisal S, Al-Abdulwahab A, Al-Aftan M, et al. Diagnostic accuracy of ultrasonography in classifying thyroid nodules compared with fine-needle aspiration. Saudi J Med Med Sci 2019;8:25-31.  Back to cited text no. 10
    
11.
Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. JAMA 2011;305:2462–3.  Back to cited text no. 11
    
12.
Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA. Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol 2002;12:1-6.  Back to cited text no. 12
    
13.
Periakaruppan G, Seshadri KG, Vignesh Krishna GM, Mandava R, Sai VPM, Rajendiran S. Correlation between ultrasound-based TIRADS and Bethesda System for reporting thyroid-cytopathology: 2-year experience at a tertiary care center in India. Indian J Endocrinol Metab 2018;22:651–5.  Back to cited text no. 13
    
14.
Brito JP, Gionfriddo MR, Al Nofal A, Boehmer KR, Leppin AL, Reading C, et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: Systematic review and meta-analysis. J Clin Endocrinol Metab 2014;99:1253–63.  Back to cited text no. 14
    
15.
Rosario PW. Thyroid nodules with atypia or follicular lesions of undetermined significance (bethesda category iii): Importance of ultrasonography and cytological subcategory. Thyroid 2014;24:1115–20.  Back to cited text no. 15
    
16.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid Cancer. Thyroid 2016;26:1–133.  Back to cited text no. 16
    
17.
Maity P, Jha AK, Sengupta M, Basu K, Chatterjee U, Ghosh S. Thyroid bethesda atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS): A heterogenous group. J Cytol 2019;36:200-4.  Back to cited text no. 17
[PUBMED]  [Full text]  
18.
Guleria P, Mani K, Agarwal S. Indian experience of AUS/FLUS diagnosis: Is it different from rest of Asia and the West?—A systematic review and meta-analysis. Gland Surg 2020. doi: 10.21037/gs-20-392.  Back to cited text no. 18
    
19.
Xie C, Cox P, Taylor N, LaPorte S. Ultrasonography of thyroid nodules: A pictorial review. Insights Imaging 2016;7:77-86.  Back to cited text no. 19
    
20.
Hoang JK, Lee WK, Lee M, Johnson D, Farrell S. US features of thyroid malignancy: Pearls and pitfalls. Radiographics 2007;27:847-65.  Back to cited text no. 20
    
21.
Chan BK, Desser TS, McDougall IR, Weigel RJ, Jeffrey RB Jr. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med 2003;22:1083–90.  Back to cited text no. 21
    
22.
Srinivas MN, Amogh VN, Gautam MS, Prathyusha IS, Vikram NR, Retnam MK, et al. A prospective study to evaluate the reliability of thyroid imaging reporting and data system in differentiation between benign and malignant thyroid lesions. J Clin Imaging Sci 2016;6:5.  Back to cited text no. 22
[PUBMED]  [Full text]  
23.
Taki S, Terahata S, Yamashita R, Kinuya K, Nobata K, Kakuda K, et al. Thyroid calcifications: Sonographic patterns and incidence of cancer. Clin Imaging 2004;28:368–71.  Back to cited text no. 23
    
24.
Baek HJ, Kim DW, Shin GW, Heo YJ, Baek JW, Lee YJ, et al. Ultrasonographic features of papillary thyroid carcinomas according to their subtypes. Front Endocrinol 2018;9:223.  Back to cited text no. 24
    
25.
Adamczewski Z, Lewiński A. Proposed algorithm for management of patients with thyroid nodules/focal lesions, based on ultrasound (US) and fine-needle aspiration biopsy (FNAB); own experience. Thyroid Res 2013;6:6.  Back to cited text no. 25
    

Top
Correspondence Address:
Dr. Moumita Sengupta
Flat no –A11, Snehaneer Apartment, 1185 Chakgaria, Kolkata - 700 094, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JOC.JOC_57_19

Rights and Permissions


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]



 

Top
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
    Materials and Me...
   Result
   Discussion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed373    
    Printed10    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal